---
title: <sup>68</sup>Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT
  for locally advanced or recurrent pancreatic cancer staging and restaging after
  chemoradiotherapy
date: '2024-08-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39113796/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240808182348&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Purpose: ^(68)Ga-labeled fibroblast activation protein inhibitor (FAPI)
  is a novel PET tracer with great potential for staging pancreatic cancer. Data on
  locally advanced or recurrent disease is sparse, especially on tracer uptake before
  and after high dose chemoradiotherapy (CRT). The aim of this study was to evaluate
  [^(68)Ga]Ga-FAPI-46 PET/CT staging in this setting. Methods: Twenty-seven patients
  with locally recurrent or locally advanced pancreatic adenocarcinoma (LRPAC n =
  15, LAPAC n ...'
disable_comments: true
---
Purpose: ^(68)Ga-labeled fibroblast activation protein inhibitor (FAPI) is a novel PET tracer with great potential for staging pancreatic cancer. Data on locally advanced or recurrent disease is sparse, especially on tracer uptake before and after high dose chemoradiotherapy (CRT). The aim of this study was to evaluate [^(68)Ga]Ga-FAPI-46 PET/CT staging in this setting. Methods: Twenty-seven patients with locally recurrent or locally advanced pancreatic adenocarcinoma (LRPAC n = 15, LAPAC n ...